KASHIF ALI
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- SILVER SPRING, MD
- NPI
- 1851423388
- Received
- $1,000,233 in 1,841 records, 2019 to 2025 ($987,233 general, $13,000 research)
- As principal investigator
- $345,984 of research payments to others in 175 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 277 | $144,918 |
| 2024 | General payment | 302 | $221,790 |
| 2023 | General payment | 274 | $168,322 |
| 2022 | General payment | 282 | $197,546 |
| 2022 | Research payment | 18 | $13,000 |
| 2021 | General payment | 246 | $133,301 |
| 2020 | General payment | 200 | $24,496 |
| 2019 | General payment | 242 | $96,857 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 246 | $695,129 |
| Consulting Fee | 111 | $171,835 |
| Travel and Lodging | 105 | $70,280 |
| Food and Beverage | 1,303 | $40,720 |
| Research payment | 18 | $13,000 |
| Honoraria | 3 | $4,025 |
| Long term medical supply or device loan | 36 | $3,163 |
| Compensation for serving as faculty or as a speaker for a medical education program | 2 | $1,350 |
| Education | 17 | $728 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-12-22 | E.R. Squibb & Sons, L.L.C. | $27 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-12-18 | ABBVIE INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-12-18 | AstraZeneca Pharmaceuticals LP | $27 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-17 | Novartis Pharmaceuticals Corporation | $30 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-12-16 | PUMA BIOTECHNOLOGY, INC. | $17 | Food and Beverage | In-kind items and services | NERLYNX Drug, ONCOLOGY | 2025 | |
| 2025-12-15 | Karyopharm Therapeutics Inc. | $135 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-12-15 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-12-12 | Janssen Biotech, Inc. | $41 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2025 | |
| 2025-12-11 | ABBVIE INC. | $694 | Travel and Lodging | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-12-11 | ABBVIE INC. | $123 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-12-11 | Merck Sharp & Dohme LLC | $29 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-12-10 | Janssen Biotech, Inc. | $24 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-12-06 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-12-04 | Adaptive Biotechnologies Corporation | $8 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-12-03 | Janssen Biotech, Inc. | $33 | Food and Beverage | In-kind items and services | CARVYKTI Drug, Oncology | 2025 | |
| 2025-12-03 | GlaxoSmithKline, LLC. | $6 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2025 | |
| 2025-12-01 | AstraZeneca Pharmaceuticals LP | $31 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $28 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2025 | |
| 2025-11-21 | Regeneron Healthcare Solutions, Inc. | $845 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-11-18 | ADC THERAPEUTICS AMERICA, INC. | $21 | Food and Beverage | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | 2025 | |
| 2025-11-17 | Merck Sharp & Dohme LLC | $26 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-11-15 | Celgene Corporation | $37 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-11-12 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-11-11 | AstraZeneca Pharmaceuticals LP | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-11-10 | Ipsen Biopharmaceuticals, Inc | $26 | Food and Beverage | In-kind items and services | Onivyde Drug, Oncology | 2025 | |
| 2025-11-06 | SOBI, INC | $4,235 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vonjo Drug, Hematology/Oncology | 2025 | |
| 2025-11-06 | AstraZeneca Pharmaceuticals LP | $2,010 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-11-06 | AstraZeneca Pharmaceuticals LP | $2,010 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-11-06 | SOBI, INC | $775 | Travel and Lodging | Cash or cash equivalent | Vonjo Drug, Hematology/Oncology | 2025 | |
| 2025-11-06 | SOBI, INC | $69 | Food and Beverage | In-kind items and services | Vonjo Drug, Hematology/Oncology | 2025 | |
| 2025-11-06 | KYOWA KIRIN, INC. | $19 | Food and Beverage | In-kind items and services | POTELIGEO Drug, MONOCLONAL ANTIBODY | 2025 | |
| 2025-11-05 | AstraZeneca Pharmaceuticals LP | $2,010 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-03 | Dendreon Pharmaceuticals LLC | $31 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-11-03 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-30 | ARRAY BIOPHARMA INC | $24 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-10-28 | AstraZeneca Pharmaceuticals LP | $31 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-10-24 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-10-23 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-10-23 | E.R. Squibb & Sons, L.L.C. | $2 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-10-21 | PFIZER INC. | $74 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-20 | Lilly USA, LLC | $26 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2025-10-16 | SHIELD THERAPEUTICS INC | $27 | Food and Beverage | In-kind items and services | ACCRUFER Drug, Hematology | 2025 | |
| 2025-10-16 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-10-14 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-10-14 | E.R. Squibb & Sons, L.L.C. | $575 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-14 | Adaptive Biotechnologies Corporation | $17 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-10-10 | GlaxoSmithKline, LLC. | $1,087 | Consulting Fee | Cash or cash equivalent | JEMPERLI Biological, ONCOLOGY | 2025 | |
| 2025-10-08 | Astellas Pharma US Inc | $33 | Food and Beverage | In-kind items and services | Cresemba Drug, Infectious Diseases | 2025 | |
| 2025-10-07 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-07 | Incyte Corporation | $19 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2025 | |
| 2025-10-06 | E.R. Squibb & Sons, L.L.C. | $862 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-06 | Pharmacosmos Therapeutics Inc. | $27 | Food and Beverage | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-10-02 | Syndax Pharmaceuticals, Inc. | $31 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-02 | Regeneron Healthcare Solutions, Inc. | $13 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-29 | Tempus AI, Inc | $103 | Food and Beverage | In-kind items and services | XT CDX Device, ONCOLOGY | 2025 | |
| 2025-09-29 | RECORDATI_RARE_DISEASES_INC. | $26 | Food and Beverage | In-kind items and services | SYLVANT Drug, ONCOLOGIC AGENT | 2025 | |
| 2025-09-26 | ABBVIE INC. | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-09-26 | ABBVIE INC. | $298 | Travel and Lodging | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-09-26 | ABBVIE INC. | $290 | Travel and Lodging | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-09-26 | ABBVIE INC. | $190 | Travel and Lodging | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-09-26 | ABBVIE INC. | $40 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-09-25 | ABBVIE INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-09-25 | BeOne Medicines USA, Inc. | $21 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-09-25 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-09-23 | Regeneron Healthcare Solutions, Inc. | $5,272 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $1,191 | Travel and Lodging | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $315 | Travel and Lodging | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $258 | Travel and Lodging | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-09-22 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-09-19 | Regeneron Healthcare Solutions, Inc. | $4,942 | Consulting Fee | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-19 | Regeneron Healthcare Solutions, Inc. | $2,636 | Consulting Fee | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-19 | Regeneron Healthcare Solutions, Inc. | $659 | Consulting Fee | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-19 | Regeneron Healthcare Solutions, Inc. | $659 | Consulting Fee | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-19 | Regeneron Healthcare Solutions, Inc. | $329 | Consulting Fee | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-19 | EMD Serono, Inc. | $26 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-18 | Regeneron Healthcare Solutions, Inc. | $1,374 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-18 | Gilead Sciences, Inc. | $31 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-09-18 | Adaptive Biotechnologies Corporation | $14 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-09-17 | Regeneron Healthcare Solutions, Inc. | $121 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-16 | Sumitomo Pharma America, Inc. | $14 | Food and Beverage | In-kind items and services | ORGOVYX Drug, PROSTATE CANCER | 2025 | |
| 2025-09-15 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-09-13 | Syndax Pharmaceuticals, Inc. | $2,875 | Consulting Fee | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | 2025 | |
| 2025-09-13 | Syndax Pharmaceuticals, Inc. | $312 | Travel and Lodging | In-kind items and services | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | 2025 | |
| 2025-09-13 | Syndax Pharmaceuticals, Inc. | $100 | Food and Beverage | In-kind items and services | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | 2025 | |
| 2025-09-13 | Syndax Pharmaceuticals, Inc. | $61 | Food and Beverage | In-kind items and services | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | 2025 | |
| 2025-09-11 | Janssen Biotech, Inc. | $35 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2025 | |
| 2025-09-08 | AstraZeneca Pharmaceuticals LP | $134 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-08 | PFIZER INC. | $27 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-09-06 | Caris MPI, Inc. | $13 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-09-04 | Novartis Pharmaceuticals Corporation | $30 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-09-04 | Novartis Pharmaceuticals Corporation | $30 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-09-04 | GlaxoSmithKline, LLC. | $20 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2025 | |
| 2025-09-03 | Dendreon Pharmaceuticals LLC | $32 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-29 | E.R. Squibb & Sons, L.L.C. | $1,725 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-27 | Merck Sharp & Dohme LLC | $27 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-08-26 | Pharmacosmos Therapeutics Inc. | $27 | Food and Beverage | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-08-25 | Bayer Healthcare Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-08-21 | E.R. Squibb & Sons, L.L.C. | $90 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-08-20 | GENZYME CORPORATION | $31 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-08-19 | Regeneron Healthcare Solutions, Inc. | $685 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-08-18 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-08-14 | GENZYME CORPORATION | $34 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-08-14 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-08-12 | Bayer Healthcare Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-08-11 | Geron Corporation | $20 | Food and Beverage | In-kind items and services | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $1,647 | Consulting Fee | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $659 | Consulting Fee | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $329 | Consulting Fee | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-08-08 | Janssen Biotech, Inc. | $24 | Food and Beverage | In-kind items and services | TALVEY Biological, Oncology | 2025 | |
| 2025-08-07 | KYOWA KIRIN, INC. | $27 | Food and Beverage | In-kind items and services | POTELIGEO Drug, MONOCLONAL ANTIBODY | 2025 | |
| 2025-08-06 | Merck Sharp & Dohme LLC | $20 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-08-06 | Incyte Corporation | $19 | Food and Beverage | Cash or cash equivalent | ZYNYZ Drug, Oncology | 2025 | |
| 2025-08-05 | E.R. Squibb & Sons, L.L.C. | $7,245 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-08-04 | Janssen Biotech, Inc. | $16 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-07-31 | BeOne Medicines USA, Inc. | $30 | Food and Beverage | In-kind items and services | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-07-29 | EMD Serono, Inc. | $16 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-28 | Janssen Biotech, Inc. | $32 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-07-25 | AstraZeneca Pharmaceuticals LP | $4,020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-07-25 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-07-24 | AstraZeneca Pharmaceuticals LP | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-07-24 | TerSera Therapeutics LLC | $37 | Food and Beverage | In-kind items and services | Xermelo Drug, Oncology | 2025 | |
| 2025-07-23 | Merck Sharp & Dohme LLC | $3,960 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-07-23 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-07-23 | E.R. Squibb & Sons, L.L.C. | $111 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-07-23 | ADC THERAPEUTICS AMERICA, INC. | $22 | Food and Beverage | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | 2025 | |
| 2025-07-22 | GENZYME CORPORATION | $145 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-07-22 | Incyte Corporation | $18 | Food and Beverage | Cash or cash equivalent | ZYNYZ Drug, Oncology | 2025 | |
| 2025-07-21 | PFIZER INC. | $28 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-07-18 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-07-15 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-07-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,010 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-14 | Acrotech Biopharma Inc. | $18 | Food and Beverage | In-kind items and services | BELEODAQ Drug, ONCOLOGY | 2025 | |
| 2025-07-11 | Regeneron Healthcare Solutions, Inc. | $1,318 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-07-10 | Legend Biotech USA Inc. | $33 | Food and Beverage | In-kind items and services | CARVYKTI Biological, Oncology | 2025 | |
| 2025-07-09 | E.R. Squibb & Sons, L.L.C. | $3,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-07-09 | E.R. Squibb & Sons, L.L.C. | $3,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-07-09 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-07-08 | Merck Sharp & Dohme LLC | $1,150 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-07-08 | Merck Sharp & Dohme LLC | $121 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-07-08 | Janssen Biotech, Inc. | $37 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2025 | |
| 2025-07-07 | PFIZER INC. | $28 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-07-03 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-07-01 | Regeneron Healthcare Solutions, Inc. | $5,272 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-07-01 | Regeneron Healthcare Solutions, Inc. | $1,480 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-07-01 | Legend Biotech USA Inc. | $150 | Food and Beverage | In-kind items and services | CARVYKTI Biological, Oncology | 2025 | |
| 2025-07-01 | Stemline Therapeutics Inc. | $17 | Food and Beverage | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-06-26 | SOBI, INC | $3,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vonjo Drug, Hematology/Oncology | 2025 | |
| 2025-06-26 | SOBI, INC | $3,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vonjo Drug, Hematology/Oncology | 2025 | |
| 2025-06-26 | SOBI, INC | $973 | Travel and Lodging | Cash or cash equivalent | Vonjo Drug, Hematology/Oncology | 2025 | |
| 2025-06-26 | Regeneron Healthcare Solutions, Inc. | $125 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-06-26 | SOBI, INC | $117 | Food and Beverage | In-kind items and services | Vonjo Drug, Hematology/Oncology | 2025 | |
| 2025-06-26 | SOBI, INC | $100 | Food and Beverage | In-kind items and services | Vonjo Drug, Hematology/Oncology | 2025 | |
| 2025-06-25 | ARRAY BIOPHARMA INC | $24 | Food and Beverage | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2025 | |
| 2025-06-25 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-06-24 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-06-20 | AstraZeneca Pharmaceuticals LP | $244 | Travel and Lodging | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-06-20 | E.R. Squibb & Sons, L.L.C. | $220 | Travel and Lodging | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-06-19 | Daiichi Sankyo Inc. | $28 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2025 | |
| 2025-06-19 | EMD Serono, Inc. | $18 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-06-18 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-06-16 | Caris MPI, Inc. | $134 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-06-16 | Bayer Healthcare Pharmaceuticals Inc. | $29 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-06-13 | Aveo Pharmaceuticals, Inc. | $77 | Education | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-06-13 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-06-13 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-06-12 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-06-12 | GlaxoSmithKline, LLC. | $29 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2025 | |
| 2025-06-12 | Janssen Biotech, Inc. | $12 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-11 | AstraZeneca Pharmaceuticals LP | $4,020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-06-11 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-06-06 | Janssen Pharmaceuticals, Inc | $29 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-06-05 | E.R. Squibb & Sons, L.L.C. | $121 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-06-04 | Daiichi Sankyo Inc. | $27 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2025 | |
| 2025-06-03 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-06-03 | Regeneron Healthcare Solutions, Inc. | $16 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-06-02 | ADC THERAPEUTICS AMERICA, INC. | $25 | Food and Beverage | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | 2025 | |
| 2025-06-02 | Caris MPI, Inc. | $14 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-05-30 | AstraZeneca Pharmaceuticals LP | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-05-29 | AstraZeneca Pharmaceuticals LP | $1,074 | Travel and Lodging | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-05-29 | AstraZeneca Pharmaceuticals LP | $125 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-05-28 | Exelixis Inc. | $24 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-27 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-05-23 | Iovance Biotherapeutics, Inc. | $27 | Food and Beverage | Cash or cash equivalent | Amtagvi Drug, Oncology | 2025 | |
| 2025-05-20 | Regeneron Healthcare Solutions, Inc. | $1,318 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-05-20 | E.R. Squibb & Sons, L.L.C. | $25 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-05-16 | E.R. Squibb & Sons, L.L.C. | $2 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-05-15 | Adaptive Biotechnologies Corporation | $161 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-05-15 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-05-15 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-05-14 | Eisai Inc. | $27 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2025 | |
| 2025-05-14 | BeOne Medicines USA, Inc. | $21 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-05-13 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-05-12 | AstraZeneca Pharmaceuticals LP | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-05-12 | Genentech USA, Inc. | $26 | Food and Beverage | In-kind items and services | Polivy Biological, BioOncology | 2025 | |
| 2025-05-08 | PharmaEssentia USA Corporation | $31 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-05-08 | Janssen Biotech, Inc. | $11 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-05-07 | Merck Sharp & Dohme LLC | $27 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 |
The latest 200 records of 1,841.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-11-30 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-11-19 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $1,900 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-10-31 | AstraZeneca Pharmaceuticals LP | MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA | $7,275 | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus t | 2025 |
| 2025-10-31 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-10-29 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $1,900 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-10-29 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $1,900 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-10-08 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-09-30 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-08-31 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-08-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2025 |
| 2025-08-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2025 |
| 2025-08-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2025 |
| 2025-08-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2025 |
| 2025-08-15 | Amgen Inc. | Maryland Oncology Hematology, P.a. | $33 | Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium | 2025 |
| 2025-08-06 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $1,900 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-08-06 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $1,900 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-08-06 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $1,900 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-07-31 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-07-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2025 |
| 2025-06-30 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-06-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2025 |
| 2025-06-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2025 |
| 2025-05-31 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-05-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2025 |
| 2025-05-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2025 |
| 2025-05-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2025 |
| 2025-05-15 | Amgen Inc. | Maryland Oncology Hematology, P.a. | $166 | MyLung Consortium Study (USOR) | 2025 |
| 2025-05-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2025 |
| 2025-05-15 | Ipsen Bioscience Inc. | US ONCOLOGY RESEARCH LLC | $1,000 | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2025 |
| 2025-05-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2025 |
| 2025-04-30 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-04-16 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $2,100 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-04-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2025 |
| 2025-04-02 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $2,100 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-03-31 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-03-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2025 |
| 2025-03-05 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $2,100 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-03-05 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $18,500 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-03-05 | JAZZ PHARMACEUTICALS INC. | Sarah Cannon Research Institute LLC | $3,500 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-02-28 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-02-12 | Janssen Research & Development, LLC | Maryland Oncology Hematlgy Silver Spg White Oak Ca | $1,125 | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T- | 2025 |
| 2025-02-12 | Janssen Research & Development, LLC | Maryland Oncology Hematlgy Silver Spg White Oak Ca | $1,125 | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T- | 2025 |
| 2025-01-31 | JAZZ PHARMACEUTICALS INC. | MARYLAND ONCOLOGY HEMATOLOGY | $1,000 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Che | 2025 |
| 2025-01-27 | AstraZeneca UK Limited | HOLY CROSS HOSPITAL | $10,950 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertini | 2025 |
| 2025-01-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2025 |
| 2025-01-15 | AstraZeneca Pharmaceuticals LP | MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA | $520 | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small C | 2025 |
| 2025-01-15 | Eli Lilly and Company | MARYLAND ONCOLOGY HEMATOLOGY PA | $433 | 2025 | |
| 2024-12-31 | AstraZeneca UK Limited | Holy Cross Hospital | $98 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertini | 2024 |
| 2024-10-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2024 |
| 2024-10-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 20381 | 2024 |
| 2024-10-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 20381 | 2024 |
| 2024-09-15 | Mirati Therapeutics, Inc. | Maryland Oncology Hematology, Pa | $100 | Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study | 2024 |
| 2024-09-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 22285 | 2024 |
| 2024-08-07 | Janssen Research & Development, LLC | The Us Oncology Ntwrk | $564 | ACE-BREAST-03 | 2024 |
| 2024-08-02 | Janssen Research & Development, LLC | The Us Oncology Ntwrk | $3,579 | ACE-BREAST-03 | 2024 |
| 2024-07-26 | Janssen Research & Development, LLC | The Us Oncology Ntwrk | $4,540 | ACE-BREAST-03 | 2024 |
| 2024-07-24 | AstraZeneca UK Limited | US Oncology Research | $11,000 | a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus ob | 2024 |
| 2024-07-19 | Janssen Research & Development, LLC | The Us Oncology Ntwrk | $1,125 | ACE-BREAST-03 | 2024 |
| 2024-07-15 | Mirati Therapeutics, Inc. | Maryland Oncology Hematology, Pa | $100 | Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study | 2024 |
| 2024-07-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 20381 | 2024 |
| 2024-07-12 | Janssen Research & Development, LLC | Maryland Oncology Hematlgy Silver Spg White Oak Ca | $12,045 | ACE-BREAST-03 | 2024 |
| 2024-05-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2024 |
| 2024-05-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2024 |
| 2024-05-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2024 |
| 2024-05-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 20381 | 2024 |
| 2024-05-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 20381 | 2024 |
| 2024-04-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 20381 | 2024 |
| 2024-04-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2024 |
| 2024-03-27 | Janssen Research & Development, LLC | Maryland Oncology Hematlgy Silver Spg White Oak Ca | $400 | ACE-BREAST-O3 | 2024 |
| 2024-03-15 | AstraZeneca Pharmaceuticals LP | MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA | $7,990 | a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus ob | 2024 |
| 2024-02-15 | Amgen Inc. | MARYLAND ONCOLOGY HEMATOLOGY P.A. | $850 | MyLung Consortium Study USOR | 2024 |
| 2024-02-15 | Mirati Therapeutics, Inc. | Maryland Oncology Hematology, Pa | $4,000 | Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study | 2024 |
| 2024-02-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 20381 | 2024 |
| 2024-02-15 | AstraZeneca Pharmaceuticals LP | MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA | $883 | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small C | 2024 |
| 2024-01-16 | AstraZeneca UK Limited | HOLY CROSS HOSPITAL OF SILVER SPRINGS, INC | $17,325 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertini | 2024 |
| 2023-12-31 | AstraZeneca UK Limited | HOLY CROSS HOSPITAL DSH | $28 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertini | 2023 |
| 2023-11-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $1,275 | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KR | 2023 |
| 2023-11-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $150 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2023 |
| 2023-11-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2023 |
| 2023-10-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 20381 | 2023 |
| 2023-10-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2023 |
| 2023-10-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2023 |
| 2023-10-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2023 |
| 2023-10-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $150 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2023 |
| 2023-10-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $150 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2023 |
| 2023-10-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $150 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2023 |
| 2023-10-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2023 |
| 2023-10-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2023 |
| 2023-10-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 20381 | 2023 |
| 2023-09-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2023 |
| 2023-09-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $16 | MYLUNG Consortium Study Protocol 2 (MYLUNG) | 2023 |
| 2023-09-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2023 |
| 2023-09-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $16 | 20381 | 2023 |
| 2023-09-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $150 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2023 |
| 2023-09-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2023 |
| 2023-09-15 | Janssen Scientific Affairs, LLC | Maryland Oncology Hematlgy Columbia | $150 | 22285 | 2023 |
| 2023-09-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $150 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2023 |
| 2023-09-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $150 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2023 |
| 2023-09-15 | Mirati Therapeutics, Inc. | MARYLAND ONCOLOGY HEMATOLOGY PA | $150 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Silver Spring, MD, county Montgomery County, MD, state Maryland; placed by its city name.
| Measure | Place (city or town) Silver Spring, MD | County Montgomery County, MD | State Maryland |
|---|---|---|---|
| Population B01003 | 81,462 | 1,065,949 | 6,206,011 |
| Population, 2020 census P1 | 81,015 | 1,062,061 | 6,177,224 |
| Median age B01002 | 35.6 | 40.2 | 39.4 |
| Under 18 B01001 | 22.2% | 22.8% | 22.2% |
| 65 and over B01001 | 12.1% | 17.0% | 16.7% |
| Households B11001 | 33,988 | 389,210 | 2,362,928 |
| Foreign born B05002 | 33.9% | 33.6% | 16.6% |
| Median household income B19013 | $99,860 | $132,450 | $103,678 |
| Median family income B19113 | $126,101 | $164,096 | $127,817 |
| Per capita income B19301 | $57,635 | $67,571 | $52,979 |
| Poverty rate B17001 | 10.6% | 7.5% | 9.4% |
| Unemployment rate B23025 | 5.4% | 4.9% | 4.9% |
| Civilian labor force B23025 | 50,814 | 590,776 | 3,313,651 |
| Mean commute (minutes) B08013 | 34.0 | 31.9 | 31.1 |
| Bachelor's degree or higher B15003 | 60.6% | 60.6% | 43.4% |
| Housing units B25001 | 35,774 | 406,531 | 2,560,784 |
| Owner-occupied B25003 | 38.3% | 65.3% | 67.6% |
| Renters B25003 | 61.7% | 34.7% | 32.4% |
| Median home value B25077 | $643,300 | $640,300 | $419,900 |
| Median gross rent B25064 | $1,913 | $2,068 | $1,705 |
| White, not Hispanic B03002 | 32.8% | 39.5% | 46.6% |
| Black B03002 | 28.3% | 18.3% | 28.9% |
| Hispanic or Latino B03002 | 24.5% | 21.0% | 12.5% |
| Asian B03002 | 8.5% | 15.3% | 6.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Silver Spring, MD.
Comments